Rapid adoption of Carterra’s LSA instrument drives European expansion
Company's antibody screening platform minimizes the risk of missing a blockbuster.
Carterra has opened a Customer Experience Center (CEC) and office in Munich, Germany. Rapid European adoption of Carterra’s platform has fueled the need for the new office.
The Munich CEC will be a place for researchers throughout Europe to gain first-hand experience with Carterra’s game-changing antibody screening platform, the LSA, through demonstrations and workshops. Carterra will also offer basic courses in label-free biosensor operation, experimental design, and data analysis. Since its launch in 2018, the LSA is installed on three continents and in a majority of the largest pharmaceutical companies in the world. To support this exponential worldwide growth, Carterra has hired direct sales, support, and service personnel in Europe, most of whom are based in the Munich office.
Traditional antibody discovery requires a primary screen of ever-expanding antibody libraries by low-resolution “yes/no” assays to identify binders. Only a small group of candidate antibodies are then characterized on traditional, low-throughput biosensor tools, which provide real-time readout of the full binding profile. This workflow runs the risk that potential blockbuster drug candidates could be missed.
Carterra’s LSA is turning that model on its head by enabling the high-resolution analysis of entire libraries, combining screening and characterization into one seamless step, thereby minimizing the risk of missing a blockbuster. The LSA’s dramatic throughput condenses months of work into days.
Additionally, the LSA offers investigators the most resolved view of the epitope – the location an antibody binds to its target. An epitope is an innate property that cannot be changed and must be discovered empirically. The LSA is the only technology that enables characterization of epitope binding at the full library level. This provides biologics developers an enormous advantage in differentiating their biomolecules from competitors’ drugs and in establishing intellectual property claims.
“The LSA is changing the way biologics are discovered,” says Tim Germann, Carterra’s Chief Commercial Officer. “We’re thrilled to invite European drug developers and the research community at large to experience in person the massive throughput and minuscule sample requirements that the LSA enables. We’re making the traditional discovery processes up to 100 times faster while using only 1% of the normal sample input-it’s the definition of disruptive.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance